Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Company to host conference and webcast on November 12, 2021 at 9:00 am ET / 6:00 am PT

BURLINGAME, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place on November 10-14, 2021.

The updated data from the mupadolimab study will be presented in a poster at SITC. Details of the poster presentation are as follows:

Title: Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: Clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)
Presenter: Jason J. Luke, M.D, University of Pittsburgh School of Medicine
Category: Immune-stimulants and immune modulators
Poster #: 701
Date & Time: Friday, November 12, 2021, 7:00 a.m. – 8:30 p.m. ET
Location: Walter E. Washington Convention Center, Hall E, or

Conference Call, Webcast and Presentation Slides
Corvus will host a conference call and webcast on November 12, 2021 at 9:00 am ET (6:00 am PT) to discuss the update on mupadolimab and other topics. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) and using the conference ID 13724618. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit

About Mupadolimab
Mupadolimab (CPI-006) is an investigational, potent humanized monoclonal antibody that is designed to react with a specific site on CD73. In preclinical studies, it has demonstrated immunomodulatory activity resulting in activation of lymphocytes, induction of antibody production from B cells and effects on lymphocyte trafficking. While there are other anti-CD73 antibodies and small molecules in development for treatment of cancer, such agents react with a different region of CD73. Mupadolimab is designed to react with a region of the molecule that acts to stimulate B cells and block production of immunosuppressive adenosine. Mupadolimab is being studied in combination with pembrolizumab in a Phase 1b/2 study in patients with advanced head and neck cancers and in patients with NSCLC that have failed chemotherapy and anti-PD(L)1 therapy. It is postulated that the activation of B cells will enhance immunity within the tumors of these patients, leading to improved clinical outcomes.

Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.

Sheryl Seapy
Real Chemistry

Primary Logo

Back to news